Overview

A Study of Opevesostat (MK-568)4 in Japanese Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-5684-005)

Status:
Active, not recruiting

Trial end date:
2026-01-12

Target enrollment:

Participant gender:

Summary

The purpose of this study is to assess the efficacy and safety of opevesostat in the treatment of Japanese men with metastatic castration-resistant prostate cancer (mCRPC) previously treated with Next Generation Hormonal Agent (NHA) and taxane-based chemotherapy.

Phase:

Phase 1

Details

Lead Sponsor:

Merck Sharp & Dohme LLC

Collaborator:

Orion Corporation, Orion Pharma

Treatments:

Dexamethasone
Fludrocortisone
Hydrocortisone